Wedbush Securities’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Wedbush Securities’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,472	Closed	-$207K	–	1123
2022 Q2	$207K	Buy	+6,472	New	+$189K	0.01%	917
2020 Q1	–	Sell	-3,235	Closed	-$257K	–	1036
2019 Q4	$257K	Buy	+3,235	New	+$192K	0.02%	737
2018 Q3	–	Sell	-8,090	Closed	-$366K	–	952
2018 Q2	$366K	Buy	+8,090	New	+$368K	0.05%	482
2018 Q1	–	Sell	-7,310	Closed	-$288K	–	909
2017 Q4	$288K	Buy	+7,310	New	+$273K	0.04%	565

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wedbush Securities's GBT Position: Q3 2022 in Review

Wedbush Securities sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 6,472 shares — an estimated $207K sold.

Wedbush Securities first reported a position in GBT in Q4 2017 and held it in 4 quarters. The position peaked at $366K in Q2 2018. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Wedbush Securities reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Wedbush Securities sold 6,472 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $207K.
Wedbush Securities first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
Wedbush Securities's Global Blood Therapeutics, Inc. position peaked at $366K in Q2 2018.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Wedbush Securities's 13F filing for Q3 2022, filed 18 Oct 2022.